Jorg Thomas Hartmann

Summary

Country: Germany

Publications

  1. doi request reprint Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO)
    Jorg Thomas Hartmann
    Abteilung Onkologie Hämatologie Immunologie Rheumatologie Pulmologie, Südwestdeutsches Tumorzentrum Comprehensive Cancer Center Tübingen, Eberhard Karls Universitat Tubingen, Germany
    Onkologie 31:237-41. 2008
  2. ncbi request reprint Toxicity of platinum compounds
    Jorg Thomas Hartmann
    Department of Hematology, Oncology, Immunology, Rheumatology, Otfried Muller Strasse 10, 72076 Tubingen, Germany
    Expert Opin Pharmacother 4:889-901. 2003
  3. ncbi request reprint Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas
    J T Hartmann
    Tuebingen University Medical Center II, Tuebingen, Germany
    Anticancer Res 23:1899-901. 2003
  4. ncbi request reprint An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma
    J T Hartmann
    Department of Medical Oncology, Hematology, Immunology, Rheumatology, Pneumology, South West German Cancer Center, Eberhard Karls University, Tuebingen, Germany
    Invest New Drugs 24:249-53. 2006
  5. pmc Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study
    J T Hartmann
    Abt Hämatologie Onkologie Immunologie Rheumatologie, Medizinische Klinik II, Eberhard Karls Universitat, Tuebingen, Germany
    Br J Cancer 89:2051-6. 2003
  6. ncbi request reprint Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil
    Joerg Thomas Hartmann
    Abt Hämatologie Onkologie Immunologie Rheumatologie, Medizinische Klinik II, Eberhard Karls Universitat, Tubingen, Germany Krankenhaus Nordwest, Frankfurt, Germany
    Anticancer Drugs 15:473-7. 2004
  7. ncbi request reprint Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group
    Jorg T Hartmann
    Department of Oncology, South West German Comprehensive Cancer Center, Eberhard Karls University of Tuebingen, Otfried Mueller Str 10, 72076 Tuebingen, Germany
    J Clin Oncol 25:5742-7. 2007
  8. ncbi request reprint Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma
    Jorg Thomas Hartmann
    Medizinische Klinik II and Interdisciplinary Sarcoma Center, Universitatsklinikum, Eberhard Karls University, Tuebingen, Germany
    Drugs 65:167-78. 2005
  9. ncbi request reprint New drug developments for patients with metastatic soft tissue sarcoma
    Jorg Thomas Hartmann
    Department of Hematology Oncology Immunology Rheumatology, UKT Medical Center II, Eberhard Karls University Tuebingen, Otfried Mueller Str 10, 72076 Tuebingen, Germany
    Curr Oncol Rep 7:300-6. 2005
  10. ncbi request reprint [Therapy for advanced colorectal carcinoma--new developments and standards]
    J T Hartmann
    Medizinische Klinik und Poliklinik II, Abteilung Hamatologie, Onkologie, Immunologie, Rheumatologie, Pulmonologie, Südwestdeutsches Tumorzentrum, Universitätsklinikum der Eberhard Karls Universität Tübingen
    Praxis (Bern 1994) 94:1949-55. 2005

Detail Information

Publications60

  1. doi request reprint Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO)
    Jorg Thomas Hartmann
    Abteilung Onkologie Hämatologie Immunologie Rheumatologie Pulmologie, Südwestdeutsches Tumorzentrum Comprehensive Cancer Center Tübingen, Eberhard Karls Universitat Tubingen, Germany
    Onkologie 31:237-41. 2008
    ..The aim of the study was to establish the recommended dose and to evaluate the safety of gefitinib plus FUFOX regimen in irinotecan-refractory colorectal carcinoma (CRC)...
  2. ncbi request reprint Toxicity of platinum compounds
    Jorg Thomas Hartmann
    Department of Hematology, Oncology, Immunology, Rheumatology, Otfried Muller Strasse 10, 72076 Tubingen, Germany
    Expert Opin Pharmacother 4:889-901. 2003
    ..This review focuses on cisplatin, carboplatin and oxaliplatin...
  3. ncbi request reprint Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas
    J T Hartmann
    Tuebingen University Medical Center II, Tuebingen, Germany
    Anticancer Res 23:1899-901. 2003
    ..The number of cytostatic agents effective in patients with advanced soft tissue sarcoma is limited. Trofosfamide, an alkylating agent, has been shown to be effective in several solid and haematological tumors...
  4. ncbi request reprint An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma
    J T Hartmann
    Department of Medical Oncology, Hematology, Immunology, Rheumatology, Pneumology, South West German Cancer Center, Eberhard Karls University, Tuebingen, Germany
    Invest New Drugs 24:249-53. 2006
    ..The aim of this trial was to evaluate the efficacy of gemcitabine in this setting...
  5. pmc Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study
    J T Hartmann
    Abt Hämatologie Onkologie Immunologie Rheumatologie, Medizinische Klinik II, Eberhard Karls Universitat, Tuebingen, Germany
    Br J Cancer 89:2051-6. 2003
    ..In gastric cancer,MMC plus infusional 5-FU/folinic acid may be a potential second-line regimen with promising antitumour activity...
  6. ncbi request reprint Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil
    Joerg Thomas Hartmann
    Abt Hämatologie Onkologie Immunologie Rheumatologie, Medizinische Klinik II, Eberhard Karls Universitat, Tubingen, Germany Krankenhaus Nordwest, Frankfurt, Germany
    Anticancer Drugs 15:473-7. 2004
    ..Elderly patients had the same probability to respond...
  7. ncbi request reprint Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group
    Jorg T Hartmann
    Department of Oncology, South West German Comprehensive Cancer Center, Eberhard Karls University of Tuebingen, Otfried Mueller Str 10, 72076 Tuebingen, Germany
    J Clin Oncol 25:5742-7. 2007
    ....
  8. ncbi request reprint Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma
    Jorg Thomas Hartmann
    Medizinische Klinik II and Interdisciplinary Sarcoma Center, Universitatsklinikum, Eberhard Karls University, Tuebingen, Germany
    Drugs 65:167-78. 2005
    ....
  9. ncbi request reprint New drug developments for patients with metastatic soft tissue sarcoma
    Jorg Thomas Hartmann
    Department of Hematology Oncology Immunology Rheumatology, UKT Medical Center II, Eberhard Karls University Tuebingen, Otfried Mueller Str 10, 72076 Tuebingen, Germany
    Curr Oncol Rep 7:300-6. 2005
    ..However, the number of effective cytotoxic agents for the treatment of patients with metastatic so-called adult soft tissue sarcoma is limited, especially when patients have failed anthracycline- and ifosfamide-based chemotherapy...
  10. ncbi request reprint [Therapy for advanced colorectal carcinoma--new developments and standards]
    J T Hartmann
    Medizinische Klinik und Poliklinik II, Abteilung Hamatologie, Onkologie, Immunologie, Rheumatologie, Pulmonologie, Südwestdeutsches Tumorzentrum, Universitätsklinikum der Eberhard Karls Universität Tübingen
    Praxis (Bern 1994) 94:1949-55. 2005
    ..However, in the last two decades it has become a well-documented survival prolonging treatment, postponing tumor symptoms in the majority of patients, and potentially curing some patients if combined with aggressive surgery...
  11. ncbi request reprint Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile
    Jorg T Hartmann
    Department of Oncology Hematology Immunology Pneumology Rheumatology, Eberhard Karls University Tubingen, UKT Medical Center II, Tubingen, Germany
    Drug Saf 29:209-30. 2006
    ..In contrast, topotecan primarily undergoes renal excretion. Regarding etoposide and teniposide, the extent of catechol formation over time during drug metabolism may be associated with a higher risk for secondary malignancies...
  12. ncbi request reprint Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine/cyclophosphamide and rituximab for relapsed B cell lymphoma
    Jorg T Hartmann
    Dept of Medical Oncology Hematology Immunology Rheumatology Pulmology, Medical Center II, Eberhard Karls University, Tuebingen, Germany
    Haematologica 91:ECR49. 2006
    ..Treatment with IVIG treatment resulted in normalization of peripheral blood counts within 7 weeks...
  13. ncbi request reprint Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines
    Jorg T Hartmann
    Medical Center II, South West German Cancer Center, Eberhard Karls University, Tuebingen, Germany
    Anticancer Drugs 18:245-54. 2007
    ....
  14. ncbi request reprint Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects
    Jorg Thomas Hartmann
    Department of Oncology Hematology Immunology Rheumatology Pneumology, South West German Cancer Center, Eberhard Karls University Tubingen, Germany
    Curr Drug Metab 10:470-81. 2009
    ....
  15. ncbi request reprint Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study
    Jorg Thomas Hartmann
    Abteilung Onkologie Hämatologie Immunologie Rheumatologie Pulmologie, Medizinische Klinik II, Eberhard Karls Universitat, Tubingen, Germany
    Onkologie 30:235-40. 2007
    ..To assess the toxicity and activity of bolus mitomycin C (MMC) in combination with a 24-hour continuous infusion of 5-fluorouracil (5-FU) in gastric cancer patients who had received at least one prior chemotherapy regimen...
  16. ncbi request reprint Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001)
    Joerg T Hartmann
    Department of Medical Oncology, Hematology, Immunology, Rheumatology, and Pulmonology, Medical Center, Eberhard Karls University, Tuebingen, Germany
    Cancer 110:861-6. 2007
    ..It has shown single-agent activity in refractory lymphoma, myeloma, and some solid tumors. A phase 2 study was initiated to evaluate the efficacy of bendamustine in previously treated patients...
  17. ncbi request reprint Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors
    J T Hartmann
    Tuebingen University Medical Center II, Tuebingen, Germany
    Ann Oncol 13:1017-28. 2002
    ..This investigation evaluates prognostic variables in patients with seminomatous and non-seminomatous extragonadal germ-cell tumors (EGCT) in order to identify relevant factors for long-term outcome following cisplatin-based chemotherapy...
  18. ncbi request reprint Long-term effects of platin and anthracycline derivatives and possible prevention strategies
    Jorg Thomas Hartmann
    Department of Hematology Oncology Immunology, Eberhard Karls University, Tubingen, Germany
    Front Radiat Ther Oncol 37:92-100. 2002
  19. ncbi request reprint Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer
    J T Hartmann
    Department of Hematology Oncology Immunology, Eberhard Karls University Medical Center II, Tubingen, Germany
    Anticancer Drugs 10:729-33. 1999
    ..Mitomycin C demonstrates single-agent activity in pretreated gastric cancer, but has only limited efficacy following cisplatin/paclitaxel-based first-line chemotherapy...
  20. ncbi request reprint Platinum organ toxicity and possible prevention in patients with testicular cancer
    J T Hartmann
    Department of Hematology Oncology Immunology, UKT Medical Center II, Eberhard Karls University, Tuebingen, Germany
    Int J Cancer 83:866-9. 1999
    ..Several strategies have been developed to reduce such side effects. Ongoing trials are investigating the role of the aminothiol amifostine as a nephro- and neuroprotectant...
  21. ncbi request reprint The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors
    J T Hartmann
    Department of Hematology and Oncology, UKT Medical Center II, Eberhard Karls University, Tubingen, Germany
    Anticancer Drugs 11:1-6. 2000
    ..This dose of amifostine may be sufficient for nephroprotection in patients without pre-existing risk factors for renal damage who undergo a restricted number of chemotherapy cycles...
  22. ncbi request reprint A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors
    J T Hartmann
    Department of Hematology and Oncology, UKT Medical Center II, Eberhard Karls University of Tubingen, Germany
    Invest New Drugs 18:281-9. 2000
    ..This may be advantageous if repetitive cycles of chemotherapy or subsequent administration of high dose chemotherapy is planned...
  23. ncbi request reprint Phase II study of continuous 120-hour-infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent gastrointestinal adenocarcinoma
    J T Hartmann
    Department of Hematology, Oncology and Immunology, Eberhard Karls University, UKT Medical Center II, Tubingen, Germany
    Anticancer Res 20:1177-82. 2000
    ..Mitomycin C has some single-agent activity in advanced gastric cancer but no substantial efficacy was seen as in heavily pretreated colorectal carcinoma...
  24. ncbi request reprint Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide
    J T Hartmann
    Department of Hematology, Oncology, Immunology, UKT Medical Center II, University of Tubingen, Germany
    Anticancer Res 20:3767-73. 2000
    ..In the light of the long-term consequences of persistent renal damage prevention of nephrotoxicity should be further improved...
  25. ncbi request reprint Advances in the treatment of testicular cancer
    Hans Georg Kopp
    Department of Medical Oncology, Medical Center II, Hematology, Rheumatology, Pneumology and Immunology, South West German Cancer Center, Eberhard Karls University of Tuebingen, Tuebingen, Germany
    Drugs 66:641-59. 2006
    ..For example, tandem high-dose chemotherapy regimens might be effective in achieving higher cure rates in these patients...
  26. doi request reprint Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie
    Salah Eddin Al-Batran
    Department of Hematology and Oncology, Krankenhaus Nordwest, Frankfurt, Germany
    J Clin Oncol 26:1435-42. 2008
    ..This study was designed to compare fluorouracil, leucovorin, and oxaliplatin with fluorouracil, leucovorin, and cisplatin in patients with advanced gastric cancer...
  27. ncbi request reprint Primary malignant sarcomas of the heart and great vessels in adult patients--a single-center experience
    Frank Mayer
    Department of Medical Oncology Hematology Immunology Rheumatology Pulmonology, UKT Medical Center, South West German Cancer Center, Eberhard Karls University Tuebingen, Otfried Mueller Str 10, 72076 Tuebingen, Germany
    Oncologist 12:1134-42. 2007
    ..Sarcomas arising in the heart or the great vessels are rare entities. The prognosis of the patients is dismal...
  28. pmc A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer
    C Kollmannsberger
    Department of Hematology Oncology, University of Tuebingen Medical Center, Tuebingen, Germany
    Br J Cancer 83:458-62. 2000
    ..While the overall acceptable toxicity allows its use in the palliative setting, it may also be an attractive option to be tested for neoadjuvant or adjuvant treatment...
  29. ncbi request reprint Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer
    J Wierecky
    Department of Oncology, Hematology, Immunology, and Rheumatology, Medizinische Klinik, University of Tuebingen Medical Center, Otfried Mueller Strasse 10, 72076 Tuebingen, Germany
    J Cancer Res Clin Oncol 131:255-60. 2005
    ..We investigated the incidence of secondary leukemia in patients treated with first-line high-dose chemotherapy (HDCT) plus autologous stem cell transplantation (PBSCT) for advanced testicular cancer...
  30. ncbi request reprint Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma
    Hans Georg Kopp
    Medical Center II, Department of Oncology, Hematology, Rheumatology, Immunology, and Pulmonology, South West German Comprehensive Cancer Center, Eberhard Karls University Tuebingen, Tuebingen, Germany
    Am J Clin Dermatol 9:207-17. 2008
    ....
  31. pmc Role of postchemotherapy surgery in the management of patients with liver metastases from germ cell tumors
    Jorg Thomas Hartmann
    Department of Hematology Oncology Immunology, UKT Medical Center II, Eberhard Karls University, Tubingen, Germany
    Ann Surg 242:260-6. 2005
    ..To evaluate the role of postchemotherapy adjunctive surgery in patients with liver metastases from germ cell cancer (GCT)...
  32. ncbi request reprint Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer
    F Honecker
    Department of Hematology Oncology, University of Tübingen Medical Center, 72076 Tubingen, Germany
    Anticancer Drugs 13:497-503. 2002
    ..Other organ toxicities apart from a slightly higher incidence of peripheral neuropathy were comparable between the two treatment protocols. Efficacy with a response rate of 50% was well preserved by this weekly regimen...
  33. ncbi request reprint Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer
    O Rick
    Department of Hematology, , Campus Virchow Klinikum, Berlin, Germany
    J Clin Oncol 19:81-8. 2001
    ..Peripheral nervous toxicity in approximately one third of patients is a disadvantage of this salvage strategy...
  34. pmc First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial
    C Bokemeyer
    Tuebingen University Medical Center II, Department of Hematology, Oncology, Rheumatology and Immunology, Eberhard Karls University, Otfried Mueller Str 10, 70276 Tuebingen, Germany
    Br J Cancer 89:29-35. 2003
    ..Compared to data of an international database analysis including 253 patients with mediastinal nonseminoma treated with conventional chemotherapy, the results may indicate that HD-VIP results in an approximately 15% survival improvement...
  35. ncbi request reprint A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer
    Christof Burkart
    Departments of Medical Oncology, Hematology, Immunology, Rheumatology, Pulmology, Medical Center II, Tubingen, Germany
    Anticancer Res 27:2845-8. 2007
    ..This study investigated the efficacy and toxicity of weekly single-agent irinotecan in patients with metastatic disease relapsing after cisplatin-based chemotherapy...
  36. doi request reprint Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
    S E Al-Batran
    Klinik für Onkologie und Hämatologie, Krankenhaus Nordwest, Frankfurt, Germany
    Ann Oncol 19:1882-7. 2008
    ..This study was designed to incorporate docetaxel into a tolerable biweekly (once every 2 weeks) oxaliplatin-based chemotherapy regimen...
  37. ncbi request reprint Disseminated epitheloid hemangioendothelioma mimicking symptoms of systemic vasculitis
    Michael Haap
    Department of Endocrinology, Metabolism, Clinical Chemistry and Vascular Medicine, University of Tubingen, Germany
    Onkologie 28:429-32. 2005
    ..Multifocal disease occurs in 10% of the cases. The clinical presentation results from occlusion of small blood vessels due to the disease itself or as a paraneoplastic syndrome...
  38. ncbi request reprint Hypersensitivity pneumonitis associated with the use of trofosfamide
    H G Kopp
    Medical Center II, Department of Oncology, Hematology, Rheumatology, Immunology, University of Tubingen, Germany
    Anticancer Drugs 15:603-4. 2004
    ..To our knowledge, this is the first reported case of exogenous allergic alveolitis after exposure to this drug...
  39. ncbi request reprint Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis
    J T Hartmann
    Tuebingen University Medical Center II, Tuebingen, Germany
    J Clin Oncol 19:1641-8. 2001
    ....
  40. ncbi request reprint Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer
    O Rick
    Department of Hematology and Oncology, Charite, Germany
    J Clin Oncol 22:3713-9. 2004
    ..To assess the role of residual tumor resection performed after high-dose chemotherapy (HDCT) in patients with relapsed or refractory germ cell tumors (GCT)...
  41. ncbi request reprint Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome
    C Bokemeyer
    Tuebingen University Medical Center II, Tuebingen, Germany
    Cancer 91:1394-401. 2001
    ..Primary radiotherapy seems to be associated with a significantly higher rate of disease recurrence, although most patients will be salvaged by subsequent chemotherapy...
  42. ncbi request reprint Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group
    C Kollmannsberger
    Department of Hematology Oncology, University of Tuebingen Medical Center, Otfried Mueller Strasse 10, 72076 Tuebingen, Germany
    J Clin Oncol 22:108-14. 2004
    ..This study investigates the activity of a gemcitabine plus oxaliplatin regimen in these patients...
  43. pmc Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer
    C Bokemeyer
    Department of Haematology Oncology, University of Tuebingen Medical Centre, Otfried Muller Strasse 10, 72076 Tuebingen, Germany
    Br J Cancer 87:1066-71. 2002
    ..Despite the frequent use of red blood cell transfusions, median haemoglobin nadirs remained about 7.5-8 g dl(-1) during therapy. A correlation of haemoglobin-values after completion of therapy to overall treatment outcome was found...
  44. pmc Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial
    O Nehls
    Department of Internal Medicine I, University Hospital, Tubingen, Germany
    Br J Cancer 98:309-15. 2008
    ..Our data suggest that the CAPOX regimen is a well-tolerated and active treatment option for advanced ECC and GBC but might produce poorer results for ICC...
  45. pmc A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation
    J T Hartmann
    Dept of Hematology and Oncology, UKT Medical Center II, , Germany
    Br J Cancer 84:313-20. 2001
    ..Larger randomized trials evaluating amifostine cytoprotection during high-dose chemotherapy are warranted...
  46. ncbi request reprint Late relapse after treatment for nonseminomatous testicular germ cell tumors according to a single center-based experience
    M A Kuczyk
    Department of Urology, Eberhard Karls University, Hoppe Seyler Str 3, 72076 Tubingen, Germany
    World J Urol 22:55-9. 2004
    ..It became evident that in selected cases chemotherapy alone can be considered a curative treatment option...
  47. pmc Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX
    O Nehls
    Department of Internal Medicine I, University Hospital, Tubingen, Germany
    Br J Cancer 96:1409-18. 2007
    ..BAX protein expression may be of central significance for clinical outcome to 5-FU-based adjuvant chemotherapy in stage III colon cancer, and bivariate analysis of p53/BAX possibly may provide further prognostic evidence...
  48. ncbi request reprint Treatment of patients with cisplatin-refractory testicular germ-cell cancer. German Testicular Cancer Study Group (GTCSG)
    C Bokemeyer
    Department of Internal Medicine, University of Tuebingen Medical Center, Germany
    Int J Cancer 83:848-51. 1999
    ..Future trials combining new active agents may examine alternating treatment strategies in patients with poor-prognostic disease or as salvage treatment...
  49. ncbi request reprint Impact of tumor size on the long-term survival of patients with early stage renal cell cancer
    M Kuczyk
    Department of Urology, Eberhard Karls University, Hoppe Seyler Strasse 3, 72076 Tubingen, Germany
    World J Urol 23:50-4. 2005
    ..The present study demonstrates the need for multivariate statistical approaches when the latest modification of the TNM classification system is critically evaluated...
  50. pmc Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials
    C Bokemeyer
    Department of Hematology Oncology, University of Tuebingen, Otfried Mueller Str 10, 72076 Tuebingen, Germany
    Br J Cancer 91:683-7. 2004
    ..In conclusion, carboplatin single agent therapy cannot be recommended as standard treatment for any patient subgroup with advanced metastatic seminoma and cisplatin-based combination regimens remain the standard of care...
  51. ncbi request reprint Therapy-related malignancies following treatment of germ cell cancer
    C Kollmannsberger
    Department of Medicine, University of Tuebingen, Germany
    Int J Cancer 83:860-3. 1999
    ..However, even the acceptably low number of therapy-related leukemias should encourage the search for equally effective but less toxic therapies...
  52. doi request reprint Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis
    Marianne Kraus
    Department of Medicine II, University of Tubingen, Tubingen, Germany
    Mol Cancer Ther 7:1940-8. 2008
    ..Ritonavir may therefore be tested clinically to improve the sensitivity of solid malignancies toward bortezomib treatment...
  53. pmc Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer
    C Bokemeyer
    Department of Hematology Oncology Immunology, Eberhard Karls University Medical Center II, , Germany
    Br J Cancer 77:1355-62. 1998
    ..Future studies should use these risk factors as important stratification criteria for trials aiming at the evaluation and prevention of cisplatin-induced ototoxicity...
  54. ncbi request reprint Anaemia in cancer patients: pathophysiology, incidence and treatment
    C Bokemeyer
    Department of Oncology, Haematology, Bone Marrow, Transplantation and Pneumology, University of Eppendorf Medical Center, Hamburg, Germany
    Eur J Clin Invest 35:26-31. 2005
    ..Finally, differences in treatment approaches between these erythropoietic proteins are discussed in order to guide treatment decisions specific for the individual patients' situation...
  55. ncbi request reprint Future prospects in the chemotherapy of metastatic nonseminomatous testicular germ-cell cancer
    J T Hartmann
    UKT University Medical Center II, Department of Hematology Oncology Immunology, Eberhard Karls University Tubingen, Germany
    World J Urol 17:324-33. 1999
    ....
  56. ncbi request reprint [Neuro-endocrine tumors of the gastrointestinal tract: epidemiology, classification, prognosis, diagnosis and therapeutic modalities]
    H R Salih
    Abteilung Hamatologie, Onkologie, Immunologie, Rheumatologie, Medizinische Klinik und Poliklinik II, Universitätsklinikum Tübingen der Eberhards Universität, Tubingen
    Praxis (Bern 1994) 94:291-302. 2005
    ..Furthermore, the value of available diagnostic techniques and the role of different therapeutic modalities like surgery, radiation, biotherapy and cytostatic chemotherapy are discussed...
  57. pmc Long-term effects on sexual function and fertility after treatment of testicular cancer
    J T Hartmann
    Department of Hematology Oncology Immunology Rheumatology, UKL Medical Center II, Eberhard Karls University, , Germany
    Br J Cancer 80:801-7. 1999
    ..Twenty-one of 40 patients were able to fulfil their wish for children, and no congenital abnormalities were observed in these children...
  58. ncbi request reprint Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors
    J T Hartmann
    Medical Center II, EberhardKarls-University Tuebingen, Germany
    J Natl Cancer Inst 93:1733-8. 2001
    ..2%; 95% CI = 0.1% to 12.2%). CONCLUSIONS: Patients with EGCTs, particularly those with retroperitoneal or nonseminomatous tumors, but also those with primary mediastinal EGCTs, are at an increased risk of metachronous testicular cancer...
  59. ncbi request reprint Symptomatic hypoglycemia during imatinib mesylate in a non-diabetic female patient with gastrointestinal stromal tumor
    M Haap
    Department of Endocrinology, Metabolism, Nephrology, Clinical Chemistry and Vascular Medicine, Eberhard Karls University of Tubingen, Tubingen, Germany
    J Endocrinol Invest 30:688-92. 2007
    ..Physicians treating patients with imatinib should be aware of the possible occurrence of hypoglycemic episodes in non-diabetic patients...
  60. ncbi request reprint Management of late recurrence of a low-grade endometrial stromal sarcoma (LGESS): treatment with letrozole
    K Krauss
    Department of Obstetrics and Gynecology, Eberhard Karls University Tuebingen, Calwestr 7, D 72076 Tuebingen, Germany
    Anticancer Res 27:3477-80. 2007
    ..The patient was treated with letrozole achieving a partial response which is lasting 39 months. Treatment is ongoing. Aromatase inhibitors represent an interesting treatment option for LGESS...